Accelovance, a Rockville, Md.-based global CRO focusing in oncology, vaccines and general medicine, and the Midwest Melanoma Partnership (MMP), a nonprofit organization dedicated to improving therapies for patients diagnosed with malignant melanoma, have entered into a strategic alliance to enhance the research and advancement of treatment options for patients suffering from melanoma.

The strategic alliance provides pharmaceutical and biotechnology companies with enhanced access to melanoma key opinion leaders, expedited contracting and protocol review within MMP’s 19 academic and community-based research center members, and Accelovance's oncology-experienced clinical and project staff within the U.S. and Europe.